Monique Minnema

 

SPECIALISMS:

  • Multiple Myeloma

  • Morbus Waldenstrom

  • AL amyloidosis

  • Phase I/II clinical studies

  • Immunotherapy

PubMed

 

Biography

Dr Monique Minnema was trained as internist and hematologist at the Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasias, like Multiple Myeloma, AL amyloidosis, and Morbus Waldenström. She is the medical head of the hematology research team which supervises more than 20 clinical studies. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias and lymphoma. She is a member of the HOVON working parties for multiple myeloma, lymphoma and the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Dr Minnema is the principal investigator of the HOVON 104 trial for patients with AL amyloidosis first line treatment, the clinical studies with the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and the checkpoint inhibitor Nivolumab in relapsed Lymphoma. Translational research focuses on the anti-apoptotic pathway in Multiple Myeloma and bone remodeling after successful anti myeloma treatment. She is a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016.

Research Projects

  • 3D bone marrow model for multiple myeloma

  • Innate immune system therapy for multiple myeloma treatment

  • Liquid biopsies in rare lymphoma cancers

  • Anti MAG IgM neuropathy and MYD88 prevalence

  • HOVON 104; A multicenter, prospective study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan and autologous stem cell transplantation in patients with de novo amyloid light chain (AL) amyloidosis

Current External Activities

  • ASH member

  • EBMT member

  • EHA Member

  • HOVON Multiple Myeloma working party

  • HOVON Lymphoma working party

  • HOVON LLPC working party

  • European Myeloma Network

  • European Waldenström Network

  • Medical advisory board patient organization Hematon

  • Medical advisory board patient organization Amyloidosis

  • Medical advisory board patients organization EWN

  • Chair international task force Bing Neel

Scientific Publications

5 most recent key publications:

  • Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19 

  • Minnema MC, E Kimby, S D’Sa, LM Fornecker, S Poulain, TJ. Snijders, E Kastritis, S Kremer, A Fitsiori,, L Simon, F Davi, M Lunn, JJ. Castillo, CJ. Patterson, M Le Garff-Tavernier, M Costopoulos, V Leblond, MJ Kersten, MA Dimopoulos, SP Treon. Guideline for the diagnosis, treatment and response criteria for Bing Neel syndrome. Haematologica 2017 Jan;102(1):43-51

  • Braham MVJ, Minnema MC, Sebestyen Z, Vyborova  A, Kuball J, Cumhur Öner F, Robin C, , Alblas J. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. OncoImmunology, 2018 Feb 22;7(6):e1434465

  • JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, G Cull, HC Schouten, WBC Stevens, JM Zijlstra, JW Baars, M Nijland, KD Mason, A Beeker, MJ van den Bent, M Beijert, M Gonzales, D de Jong, JK Doorduijn. Role of Rituximab in Primary Central Nervous System Lymphoma Patients: Results of the Randomised Phase III HOVON 105 / ALLG NHL 24 Intergroup Study. Lancet Oncol. 2019 Feb;20(2):216-228.

  • SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, MA Shipp, S Rodig, A Ligon, MGM Roemer, N Reddy, JB Cohen, S Assouline, M Poon, M Sharma, K Kato, S Samakoglu, A Sumbul, A Grigg.  Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Who Have Failed or Are Ineligible For Autologous Hematopoietic Cell Transplantation: A Single-Arm, Phase II Study, J Clin Oncol. 2019 Feb 20;37(6):481-489. 

GRANTS

  1. HOVON 104, A Multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan and autologous stemcell transplantation in patients with de novo AL amyloidosis, Project Leader, Dutch Cancer Society/KWF; 2010

  2. In collaboration; Seed grant Life sciences University Utrecht & UMC Utrecht;  An ex vivo three-dimensional bio-reconstituted bone marrow niche to study normal hematopoiesis and bone-residing malignancies; 2013

  3. American Institute for Cancer Research; Unraveling and Modulation of microenvironment-mediated immune resistance in Multiple Myeloma, Principal Investigator, 2013

  4. A 3D bioprinted bone marrow model to investigate the interaction between primary multiple myeloma cells and the microenvironment, Project Leader, Celgene, 2016

  5. Personal strategy to avert drug resistance in hematologic cancers. Principal Investigator, Dutch Cancer Society/KWF 2017, Project 11108

  6. 3D organoid bone marrow model to predict treatment responses in multiple myeloma patients. Spafima private fund, 2018

Clinical trials

  • ZUma-1: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

  • ZUMA-3: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)

  • AMG701: Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

  • Andromeda: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

  • BO39813: A phase IB/II study of Cobimetinib administered as single agent and in combination with Venetoclax, with or without Atezolizumab, in patients with relapsed and refractory multiple myeloma

  • CC-220: A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Associated Team Members

  • Reinier Raymakers (hematologist)

  • Margot Jak (hematologist)

  • Rimke Oostvogels (hematologist)

  • Clinical study team members;
    Anna van Muijden, Klaartje Nijssen, Linda van Dommelen, Lisette Kamps  (trial managers), 
    Els Spelt-Buchner (trial coördinator), 
    Tine Woudenberg (secretary),
    Mirjam Kruizinga-Hartgers, Lieke Simons, Karry Meertens (research nurses)